Market Place
Sourcing Support
IASO Bio Cleared By Japan`s PMDA For CAR-T Therapy Trial
24 Mar 2026 //
PR NEWSWIRE
Iaso Therapeutics Showcases mQ? Vaccine at 2026 World Congress
18 Feb 2026 //
PR NEWSWIRE
Hong Kong Approves IASO Bio`s Fucaso for R/R Myeloma
27 Nov 2025 //
PR NEWSWIRE
IASO Bio Partners With GC Cell For CAR-T Therapy In Korea
29 Oct 2025 //
PR NEWSWIRE
IASO Bio’s Anti-GPRC5D CAR-T RD118 Shows Promise in R/R Myeloma
22 Oct 2025 //
PR NEWSWIRE
IASO Bio Gets Japan Approval For BCMA CAR-T Trial
21 Oct 2025 //
PR NEWSWIRE
Cell Reports IASO Bio`s Anti-BCMA CAR-T For MS
16 Oct 2025 //
PR NEWSWIRE
IASO Bio Presents 3-Year Follow-Up Data on Fucaso CAR-T Therapy
18 Sep 2025 //
PR NEWSWIRE
IASO Bio Reveals Equecabtagene Autoleucel for Multiple Sclerosis
12 Sep 2025 //
PR NEWSWIRE
IASO Bio shows Equecabtagene Autoleucel efficacy in MS at EAN
22 Jun 2025 //
PR NEWSWIRE
IASO Opens Shanghai R&D Center, hosts Cell Therapy Globalization
20 May 2025 //
PR NEWSWIRE
IASO Bio`s NDA For Equecabtagene Autoleucel Approved by Macau Bureau
28 Mar 2025 //
PR NEWSWIRE
IASO Bio’s NDA For Equecabtagene Autoleucel Accepted In HK
14 Feb 2025 //
PR NEWSWIRE
IASO Announce Acceptance of NDA for Equecabtagene Autoleucel by HAS
29 Jan 2025 //
PR NEWSWIRE
IASO Bio Presents CAR T-Cell Persistence Study for Myeloma
09 Dec 2024 //
PR NEWSWIRE
JAMA Publishes IASO Bio`s Equecabtagene Autoleucel MM Data
07 Nov 2024 //
PR NEWSWIRE
IASO Bio Presented Outcomes Of R/RMM Patients At IMS Meeting
27 Sep 2024 //
PR NEWSWIRE
Innovent Biologics & IASO Bio enter strategic collaboration in cell therapy
08 Jul 2024 //
PHARMABIZ
IASO Bio Presents Clinical Data On Equecabtagene Autoleucel At EAN Congress 2024
01 Jul 2024 //
PR NEWSWIRE
IASO`s GPRC5D CAR-T RD118 Receives IND Approval From NMPA For Multiple Myeloma
28 Jun 2024 //
PR NEWSWIRE
IASO Single-Cell Omics On Autoimmune CNS Therapy In Science
10 May 2024 //
PR NEWSWIRE
IASO NMPA`s IND Approval for Equecabtagene Autoleucel for Treatment of Myeloma
29 Mar 2024 //
PR NEWSWIRE
IASO Bio and Innovent Present New Data of FUCASO for Multiple Myeloma
11 Dec 2023 //
PR NEWSWIRE
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO
28 Sep 2023 //
PR NEWSWIRE
Innovent and IASO Bio Present Updated Data for BCMA CAR-T FUCASO
28 Sep 2023 //
PR NEWSWIRE
China approves BCMA CAR-T therapy for multiple myeloma
03 Jul 2023 //
ENDPTS
IASO & Innovent Announce the NMPA Approval of NDA for Equecabtagene Autoleucel
02 Jul 2023 //
PR NEWSWIRE
IASO Bio Receives FDA Approval of IND Application for IASO-782
17 Jun 2023 //
PR NEWSWIRE
IASO Bio & Innovent Updated Efficacy and Safety Data of Equecabtagene Autoleucel
05 Jun 2023 //
PR NEWSWIRE
IASO Bio Announces CT103A Granted RMAT and Fast Track Designations by the FDA
12 Feb 2023 //
PR NEWSWIRE
IASO Bio Raises Nearly $75 Million in Series C1 Funding
17 Jan 2023 //
PR NEWSWIRE
